JP2018509148A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509148A5 JP2018509148A5 JP2017547087A JP2017547087A JP2018509148A5 JP 2018509148 A5 JP2018509148 A5 JP 2018509148A5 JP 2017547087 A JP2017547087 A JP 2017547087A JP 2017547087 A JP2017547087 A JP 2017547087A JP 2018509148 A5 JP2018509148 A5 JP 2018509148A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- immune cells
- cell
- allogeneic
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 13
- 210000002865 immune cell Anatomy 0.000 claims 10
- 230000000735 allogeneic effect Effects 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 6
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 5
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 5
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 claims 5
- 101710197836 HLA class I histocompatibility antigen, alpha chain G Proteins 0.000 claims 5
- 230000001506 immunosuppresive effect Effects 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 230000002779 inactivation Effects 0.000 claims 4
- 230000003612 virological effect Effects 0.000 claims 4
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000415 inactivating effect Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102100030346 Antigen peptide transporter 1 Human genes 0.000 claims 1
- 102100031780 Endonuclease Human genes 0.000 claims 1
- 108010042407 Endonucleases Proteins 0.000 claims 1
- 101710086766 FP protein Proteins 0.000 claims 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 1
- 101100048372 Human cytomegalovirus (strain AD169) H301 gene Proteins 0.000 claims 1
- 101100048373 Human cytomegalovirus (strain Merlin) UL18 gene Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102000043129 MHC class I family Human genes 0.000 claims 1
- 108091054437 MHC class I family Proteins 0.000 claims 1
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 101710163270 Nuclease Proteins 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 101150037769 TRX2 gene Proteins 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000002688 persistence Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201570138 | 2015-03-11 | ||
| DKPA201570138 | 2015-03-11 | ||
| PCT/EP2016/055332 WO2016142532A1 (en) | 2015-03-11 | 2016-03-11 | Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018509148A JP2018509148A (ja) | 2018-04-05 |
| JP2018509148A5 true JP2018509148A5 (enExample) | 2019-04-11 |
Family
ID=52682595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017547087A Pending JP2018509148A (ja) | 2015-03-11 | 2016-03-11 | 患者における持続性および／または生着を増加させるために同種ｔ細胞を改変する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11186824B2 (enExample) |
| EP (1) | EP3268388A1 (enExample) |
| JP (1) | JP2018509148A (enExample) |
| KR (1) | KR20170137079A (enExample) |
| CN (1) | CN107683333A (enExample) |
| AU (1) | AU2016231061B2 (enExample) |
| BR (1) | BR112017018224A2 (enExample) |
| CA (1) | CA2978840A1 (enExample) |
| IL (1) | IL253879A0 (enExample) |
| MX (1) | MX2017011418A (enExample) |
| RU (1) | RU2017134441A (enExample) |
| WO (1) | WO2016142532A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE048558T2 (hu) * | 2014-03-11 | 2020-07-28 | Cellectis | Eljárás allogén transzplantációra kompatibilis T-sejtek létrehozására |
| CN108135935A (zh) | 2015-07-21 | 2018-06-08 | 儿童医疗中心有限公司 | 表达pd-l1的造血干细胞及其用途 |
| BR112018011089A2 (pt) | 2015-12-04 | 2018-12-04 | Intellia Therapeutics Inc | composições e métodos para a imuno-oncologia |
| CA3037528A1 (en) * | 2016-09-23 | 2018-03-29 | University Of Southern California | Chimeric antigen receptors and compositions and methods of use thereof |
| WO2018115189A1 (en) | 2016-12-21 | 2018-06-28 | Cellectis | Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy |
| BR112019014257A2 (pt) * | 2017-01-13 | 2020-04-28 | Univ California | método para gerar uma célula-tronco pluripotente hipoimunogênica, célula-tronco pluripotente hipoimunogênica humana, método para produzir uma célula pluripotente hipoimunogênica, e ss-2 microglobulina |
| JP2020513832A (ja) | 2017-03-22 | 2020-05-21 | ノバルティス アーゲー | 免疫腫瘍学のための組成物および方法 |
| US20200399343A1 (en) * | 2017-04-19 | 2020-12-24 | Allogene Therapeutics, Inc. | Improved t cell compositions and methods |
| CN107177632B (zh) * | 2017-05-27 | 2020-02-07 | 上海优卡迪生物医药科技有限公司 | 一种基于octs技术的髓系白血病car-t治疗载体及其构建方法和应用 |
| PE20241587A1 (es) | 2017-06-02 | 2024-08-01 | Pfizer | Receptores de antigenos quimericos que se dirigen a flt3 |
| US11879137B2 (en) | 2017-09-22 | 2024-01-23 | The Children's Medical Center Corporation | Treatment of type 1 diabetes and autoimmune diseases or disorders |
| WO2019076486A1 (en) * | 2017-10-19 | 2019-04-25 | Cellectis | TARGETED GENE INTEGRATION OF NK INHIBITOR GENES FOR ENHANCED IMMUNE CELL THERAPY |
| CN109836497A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种靶向egfr的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| EP3694546A1 (en) | 2018-01-30 | 2020-08-19 | Cellectis | Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen |
| WO2019154313A1 (zh) * | 2018-02-11 | 2019-08-15 | 江苏恒瑞医药股份有限公司 | 一种分离的嵌合抗原受体以及包含其的修饰t细胞及用途 |
| JP7584127B2 (ja) * | 2018-04-26 | 2024-11-15 | ベイラー カレッジ オブ メディスン | 活性化された病原性ｔ細胞およびｎｋ細胞の選択的標的化のための自己／同種免疫防御受容体 |
| GB201813178D0 (en) * | 2018-08-13 | 2018-09-26 | Autolus Ltd | Cell |
| WO2020051562A2 (en) | 2018-09-07 | 2020-03-12 | Beam Therapeutics Inc. | Compositions and methods for improving base editing |
| CN109055380B (zh) * | 2018-09-19 | 2021-08-27 | 深圳市菲鹏生物治疗股份有限公司 | 一种通用型car-t细胞的制备方法 |
| US20220017926A1 (en) * | 2018-09-21 | 2022-01-20 | Cafa Therapeutics Limited | Method for gene editing of cell on the basis of crispr/cas system |
| CN109293773B (zh) * | 2018-09-25 | 2020-09-04 | 上海邦耀生物科技有限公司 | 靶向cd38蛋白的抗体、嵌合抗原受体和药物 |
| EP4578507A3 (en) * | 2018-11-01 | 2025-11-12 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for t cell engineering |
| CN113227141A (zh) * | 2018-11-07 | 2021-08-06 | 克里斯珀医疗股份公司 | 抗cd33免疫细胞癌症疗法 |
| MX2021009744A (es) | 2019-02-15 | 2021-11-12 | Univ Southern California | Composiciones de anticuerpos lym-1 y lym-2 y constructos car mejorados. |
| CA3130698A1 (en) * | 2019-03-18 | 2020-09-24 | Steven John GRECO | Methods and clinical protocols and kits pertaining to making and using therapeutic compositions for cellular treatment |
| WO2020214606A1 (en) * | 2019-04-15 | 2020-10-22 | The Medical College Of Wisconsin, Inc. | Recombinant pd-l1 peptides and methods of use |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| BR112021022458A2 (pt) | 2019-05-10 | 2021-12-28 | Univ California | Células pluripotentes modificadas ou uma célula derivada das mesmas, método de transplantar uma célula, método de tratamento de uma doença em um paciente em necessidade de células transplantadas, método para gerar uma célula pluripotente modificada, método para gerar uma célula hipoimunogênica pluripotente, e método de transplante de uma célula pluripotente hipoimunogênica (hip) ou célula derivada da mesma |
| US20220251576A1 (en) * | 2019-06-26 | 2022-08-11 | Takeda Pharmaceutical Company Limited | Transfection method |
| EP4003375A4 (en) * | 2019-07-31 | 2023-09-06 | Forty Seven, Inc. | DEPLETION DIETS FOR MODIFIED T CELL OR NK CELL THERAPY |
| BR112022011399A2 (pt) | 2019-12-11 | 2022-08-30 | A2 Biotherapeutics Inc | Receptor de antígeno quimérico baseado em lilrb1 |
| KR102246067B1 (ko) * | 2020-05-13 | 2021-04-29 | (주)세렌라이프 | 효능이 증진된 줄기세포를 포함하는 세포 생착능 증진용 조성물 |
| JP7742651B2 (ja) * | 2020-05-26 | 2025-09-22 | 株式会社ヘリオス | 低免疫原性細胞 |
| HUE067417T2 (hu) | 2020-08-20 | 2024-10-28 | A2 Biotherapeutics Inc | Készítmények és módszerek EGFR-pozitív rákok kezelésére |
| MX2023002041A (es) | 2020-08-20 | 2023-04-27 | A2 Biotherapeutics Inc | Composiciones y métodos para tratar cánceres positivos para mesotelina. |
| CN116724052A (zh) | 2020-08-20 | 2023-09-08 | A2生物治疗股份有限公司 | 用于治疗ceacam阳性癌症的组合物和方法 |
| AU2021386366A1 (en) * | 2020-11-24 | 2023-06-29 | A2 Biotherapeutics, Inc. | Adoptive cell therapy for treatment of cancer associated with loss of heterozygosity |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| WO2022192895A1 (en) * | 2021-03-10 | 2022-09-15 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Compositions and methods to reduce therapeutic t cell toxicity |
| JP2025521731A (ja) | 2022-07-01 | 2025-07-10 | ノヴォ ノルディスク アー／エス | 腹側中脳神経系前駆細胞のニューロン分化の強化 |
| WO2025003393A1 (en) | 2023-06-30 | 2025-01-02 | Novo Nordisk A/S | Enhancing neuronal differentiation of neural progenitor cells |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
| WO2001062895A2 (en) | 2000-02-24 | 2001-08-30 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US20060222633A1 (en) | 2000-05-11 | 2006-10-05 | Yale University | Prevention, decrease, and/or treatment of immunoreactivity by depleting and/or inactivating antigen presenting cells in the host |
| US7094874B2 (en) * | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| EP1620537B1 (en) | 2003-03-14 | 2012-10-24 | Cellectis SA | Large volume ex vivo electroporation method |
| WO2005097160A2 (en) | 2004-04-05 | 2005-10-20 | The Regents Of The University Of California | Modulation of nkg2d |
| US8986712B2 (en) | 2009-11-29 | 2015-03-24 | Yeda Research And Development Co., Ltd. | Peptides derived from HIV-1 gp41 transmembrane domain for t-immunomodulation |
| ES2638521T5 (es) * | 2010-03-05 | 2021-03-02 | Univ Johns Hopkins | Composiciones y métodos para anticuerpos y proteínas de fusión inmunomoduladores dirigidos contra dianas |
| WO2012138927A2 (en) | 2011-04-05 | 2012-10-11 | Philippe Duchateau | Method for the generation of compact tale-nucleases and uses thereof |
| IL318221A (en) | 2012-05-15 | 2025-03-01 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting PD–1/PD–L1 signaling |
| US20150017136A1 (en) | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
| WO2013176915A1 (en) * | 2012-05-25 | 2013-11-28 | Roman Galetto | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| RU2663725C2 (ru) | 2012-09-04 | 2018-08-08 | Селлектис | Многоцепочечный химерный антигенный рецептор и его применения |
| US9902973B2 (en) | 2013-04-11 | 2018-02-27 | Caribou Biosciences, Inc. | Methods of modifying a target nucleic acid with an argonaute |
| CN105378067A (zh) * | 2013-05-13 | 2016-03-02 | 塞勒克提斯公司 | 工程化用于免疫治疗的高活性t细胞的方法 |
| WO2014191128A1 (en) * | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| PT3105317T (pt) | 2014-02-14 | 2019-02-27 | Cellectis | Células para imunoterapia manipuladas para atuar sobre antigénios presentes tanto em células imunitárias como em células patológicas |
| PT3119807T (pt) | 2014-03-19 | 2019-09-04 | Cellectis | Recetores de antigénios quiméricos específicos de cd123 para imunoterapêutica do cancro |
-
2016
- 2016-03-11 RU RU2017134441A patent/RU2017134441A/ru not_active Application Discontinuation
- 2016-03-11 CA CA2978840A patent/CA2978840A1/en active Pending
- 2016-03-11 CN CN201680014457.5A patent/CN107683333A/zh active Pending
- 2016-03-11 US US15/556,558 patent/US11186824B2/en active Active
- 2016-03-11 BR BR112017018224A patent/BR112017018224A2/pt not_active IP Right Cessation
- 2016-03-11 MX MX2017011418A patent/MX2017011418A/es unknown
- 2016-03-11 JP JP2017547087A patent/JP2018509148A/ja active Pending
- 2016-03-11 EP EP16710948.7A patent/EP3268388A1/en active Pending
- 2016-03-11 AU AU2016231061A patent/AU2016231061B2/en active Active
- 2016-03-11 KR KR1020177028154A patent/KR20170137079A/ko not_active Withdrawn
- 2016-03-11 WO PCT/EP2016/055332 patent/WO2016142532A1/en not_active Ceased
-
2017
- 2017-08-07 IL IL253879A patent/IL253879A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018509148A5 (enExample) | ||
| Haubner et al. | Cooperative CAR targeting to selectively eliminate AML and minimize escape | |
| RU2017134441A (ru) | Способы конструирования аллогенных т-клеток для повышения их персистенции и/или приживления у пациентов | |
| Lawand et al. | Key features of gamma-delta T-cell subsets in human diseases and their immunotherapeutic implications | |
| Vella et al. | CD4+ T cell differentiation in chronic viral infections: the Tfh perspective | |
| Starbeck-Miller et al. | Cutting edge: Expression of FcγRIIB tempers memory CD8 T cell function in vivo | |
| Dolcetti et al. | Immunotherapy for gastric cancer: time for a personalized approach? | |
| JP2019528769A5 (enExample) | ||
| Kamphorst et al. | CD4 T-cell immunotherapy for chronic viral infections and cancer | |
| WO2018023025A8 (en) | Combination therapies of chimeric antigen receptors and pd-1 inhibitors | |
| JP2017535284A5 (enExample) | ||
| Zamarin et al. | Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer | |
| JP2019531745A5 (enExample) | ||
| WO2013176916A8 (en) | Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells | |
| JP2018529327A5 (enExample) | ||
| WO2019232409A9 (en) | Methods for genome editing and activation of cells | |
| CA2924252C (en) | Bi- or multispecific polypeptides binding immune effector cell surface antigens and hbv antigens for treating hbv infections and associated conditions | |
| JP2017538401A5 (enExample) | ||
| PH12020551124A1 (en) | Bispecific antibody | |
| RU2015155821A (ru) | Вакцины против малярии | |
| JP2015143226A5 (enExample) | ||
| Boettcher et al. | Development of CAR T cell therapy in children—A comprehensive overview | |
| JP2018509163A5 (enExample) | ||
| JP2017513472A5 (enExample) | ||
| De Bousser et al. | T cell engaging immunotherapies, highlighting chimeric antigen receptor (CAR) T cell therapy |